ALZN Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 10.55%

Insider Buying (Last 12 Months): $1,358.05

Insider Selling (Last 12 Months): $0.00

Alzamend Neuro Insider Trading History Chart

Alzamend Neuro Share Price & Price History

^$0.68

▼ -0.0125 (-1.81%)

As of 03/14/2025 05:00 PM ET

Days: 30 | 90 | 365

Alzamend Neuro Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2025	Milton C. Ault III	Director	Buy	100	$0.68	$68.00	77,368
8/6/2024	Milton C. Ault III	Director	Buy	75	$2.75	$206.25	77,268
7/31/2024	Milton C. Ault III	Director	Buy	25	$3.74	$93.50	77,193
4/19/2024	Milton C. Ault III	Director	Buy	100	$6.90	$690.00	77,169
4/1/2024	Milton C. Ault III	Director	Buy	33	$9.10	$300.30	77,069
1/5/2024	Milton C. Ault III	Director	Buy	500	$10.20	$5,100.00	76,836
12/26/2023	Milton C. Ault III	Major Shareholder	Buy	50	$9.00	$450.00	2,603
12/22/2023	Milton C. Ault III	Major Shareholder	Buy	20	$9.20	$184.00	16,686
9/26/2023	David J Katzoff	CFO	Buy	353	$28.50	$10,060.50	540
5/24/2023	Milton C. Ault III	Major Shareholder	Buy	120	$88.50	$10,620.00	2,553
4/28/2023	Stephan Jackman	CEO	Buy	246	$81.00	$19,926.00	303
3/22/2023	Lynne Fahey Mcgrath	Director	Buy	66	$64.50	$4,257.00	66
3/16/2023	Milton C. Ault III	Major Shareholder	Buy	26	$75.00	$1,950.00	73,700
2/15/2023	Milton C. Ault III	Major Shareholder	Buy	6	$90.00	$540.00	73,673
12/27/2022	Milton C. Ault III	Major Shareholder	Buy	6	$88.50	$531.00	73,646
11/18/2022	Milton C. Ault III	Major Shareholder	Buy	6	$193.50	$1,161.00	73,586
10/31/2022	Milton C. Ault III	Major Shareholder	Buy	40	$178.50	$7,140.00	67,351
10/12/2022	Milton C. Ault III	Major Shareholder	Buy	13	$184.50	$2,398.50	67,311
10/6/2022	Milton C. Ault III	Major Shareholder	Buy	6	$214.50	$1,287.00	67,297
9/29/2022	Milton C. Ault III	Major Shareholder	Buy	23	$178.50	$4,105.50	67,291
9/19/2022	Stephan Jackman	CEO	Buy	56	$184.50	$10,332.00	56
9/14/2022	David J Katzoff	CFO	Buy	66	$166.50	$10,989.00	186
8/25/2022	Milton C. Ault III	Major Shareholder	Buy	32	$144.00	$4,608.00	66,717
8/22/2022	Milton C. Ault III	Major Shareholder	Buy	240	$145.50	$34,920.00	66,684
8/15/2022	Milton C. Ault III	Major Shareholder	Buy	93	$159.00	$14,787.00	66,344
8/3/2022	Milton C. Ault III	Major Shareholder	Buy	13	$142.50	$1,852.50	66,244
7/27/2022	Milton C. Ault III	Major Shareholder	Buy	38	$130.50	$4,959.00	66,231
7/22/2022	Milton C. Ault III	Major Shareholder	Buy	15	$136.50	$2,047.50	66,193
7/18/2022	Milton C. Ault III	Major Shareholder	Buy	66	$147.00	$9,702.00	66,177
6/29/2022	Milton C. Ault III	Major Shareholder	Buy	66	$132.00	$8,712.00	66,111
6/17/2022	Milton C. Ault III	Major Shareholder	Buy	66	$132.00	$8,712.00	66,044
6/14/2022	Milton C. Ault III	Major Shareholder	Buy	66	$127.50	$8,415.00	65,911
6/7/2022	Milton C. Ault III	Major Shareholder	Buy	13	$141.00	$1,833.00	65,791
6/2/2022	Milton C. Ault III	Major Shareholder	Buy	53	$144.00	$7,632.00	65,777
5/26/2022	Milton C. Ault III	Major Shareholder	Buy	66	$136.50	$9,009.00	65,644
5/24/2022	Milton C. Ault III	Major Shareholder	Buy	107	$133.50	$14,284.50	65,577
5/17/2022	Milton C. Ault III	Major Shareholder	Buy	159	$147.00	$23,373.00	65,437
5/12/2022	Milton C. Ault III	Major Shareholder	Buy	166	$127.50	$21,165.00	65,277
5/5/2022	Milton C. Ault III	Major Shareholder	Buy	666	$160.50	$106,893.00	2,166
4/26/2022	Milton C. Ault III	Major Shareholder	Buy	17,777	$225.00	$3,999,825.00	64,444
4/22/2022	Milton C. Ault III	Major Shareholder	Buy	500	$141.00	$70,500.00	1,500
4/11/2022	Milton C. Ault III	Major Shareholder	Buy	333	$169.50	$56,443.50	1,000
3/31/2022	Mark Gustafson	Director	Sell	133	$181.50	$24,139.50	400
3/18/2022	Milton C. Ault III	Major Shareholder	Buy	666	$165.00	$109,890.00

See Full Table

SEC Filings (Institutional Ownership Changes) for Alzamend Neuro (NASDAQ:ALZN)

49.61% of Alzamend Neuro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Alzamend Neuro Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/17/2025	Citadel Advisors LLC	30,638	$36K	0.0%	N/A	0.564%
2/12/2025	Geode Capital Management LLC	33,540	$39K	0.0%	N/A	0.618%
5/20/2024	Virtu Financial LLC	26,482	$26K	0.0%	N/A	0.385%
2/2/2024	Truist Financial Corp	154,327	$0.14M	0.0%	-93.3%	2.168%
5/11/2022	RFG Advisory LLC	250,000	$0.31M	0.0%	N/A	0.277%
5/9/2022	Qube Research & Technologies Ltd	78,465	$97K	0.0%	N/A	0.087%
4/22/2022	Truist Financial Corp	2,314,907	$2.85M	0.0%	N/A	2.569%
1/31/2022	Commonwealth Equity Services LLC	116,666	$0.22M	0.0%	N/A	0.131%
11/16/2021	Schonfeld Strategic Advisors LLC	31,600	$97K	0.0%	N/A	0.036%
11/16/2021	Two Sigma Investments LP	172,913	$0.53M	0.0%	N/A	0.199%
11/16/2021	Warberg Asset Management LLC	14,000	$43K	0.0%	N/A	0.016%
11/15/2021	Sassicaia Capital Advisers LLC	93,762	$0.29M	0.8%	N/A	0.108%
9/17/2021	Virtu Financial LLC	15,402	$0.14M	0.0%	N/A	0.018%
8/16/2021	Cubist Systematic Strategies LLC	23,672	$0.21M	0.0%	N/A	0.028%
8/13/2021	Geode Capital Management LLC	44,600	$0.39M	0.0%	N/A	0.052%
8/11/2021	Susquehanna International Group LLP	57,030	$0.50M	0.0%	N/A	0.067%

Data available starting January 2016

See Full Table

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Today's Range

Now: $0.68

$0.64

$0.70

50 Day Range

MA: $1.02

$0.67

$1.27

52 Week Range

Now: $0.68

$0.64

$15.06

Volume

63,378 shs

Average Volume

559,816 shs

Market Capitalization

$4.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Alzamend Neuro?: Alzamend Neuro's top insider shareholders include:
Milton C Ault III (Director)
Milton C Ault III (Major Shareholder)
David J Katzoff (CFO)
Stephan Jackman (CEO)
Lynne Fahey Mcgrath (Director)
Learn More about top insider investors at Alzamend Neuro.
Who are the major institutional investors of Alzamend Neuro?: Alzamend Neuro's top institutional shareholders include:
Geode Capital Management LLC — 0.62%
Citadel Advisors LLC — 0.56%
Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Alzamend Neuro stock.
Which institutional investors are buying Alzamend Neuro stock?: During the previous quarter, ALZN stock was purchased by institutional investors including:
Geode Capital Management LLC
Citadel Advisors LLC
In the last year, these company insiders have bought Alzamend Neuro stock:
Milton C Ault III (Director)
Milton C Ault III (Major Shareholder)
David J Katzoff (CFO)
Stephan Jackman (CEO)
Lynne Fahey Mcgrath (Director)
Learn More investors buying Alzamend Neuro stock.